Table 2 Correlations between PHLDA3 expression and clinicopathological factors in lung adenocarcinoma.
n | PHLDA3-negative | PHLDA3-positive | p value | |
|---|---|---|---|---|
Age | 0.352 | |||
<60 | 64 | 38(59.4%) | 26(40.6%) | |
≥60 | 44 | 30(68.2%) | 14(31.8%) | |
Sex | 0.373 | |||
Male | 60 | 40(66.7%) | 20(33.3%) | |
Female | 48 | 28(58.3%) | 20(41.7%) | |
Differentiation | 0.185 | |||
Well | 13 | 11(84.6%) | 2(15.4%) | |
Moderate | 64 | 37(57.8%) | 27(42.2%) | |
Poor | 31 | 20(64.5%) | 11(35.5%) | |
TNM stages | 0.004 | |||
I | 16 | 15(93.8%) | 1(6.3%) | |
II | 66 | 42(63.6%) | 24(36.4%) | |
III–IV | 26 | 11(42.3%) | 15(57.7%) | |
Lymphatic metastasis | 0.032 | |||
Yes | 64 | 35(54.7%) | 29(45.3%) | |
No | 44 | 33(75.0%) | 11(25.0%) | |
Tumor status | 0.003 | |||
T1 | 24 | 22(91.7%) | 2(8.3%) | |
T2 | 66 | 38(57.6%) | 28(42.4%) | |
T3–T4 | 18 | 8(44.4%) | 10(55.6%) |
